BLACK mobile logo

united states

Abortion foes eye Interpol’s global law enforcement network to target abortion pills

August 17, 2026

The Charlotte Lozier Institute, an anti-abortion research organization, has outlined a new approach to restrict medication abortion access by urging Attorney General Todd Blanche to deploy Operation Pangea, an international program typically used to combat counterfeit pharmaceuticals. Attorney Mary Harned proposed using this enforcement mechanism to argue that overseas mifepristone creates confusion between legitimate and illegitimate drugs, potentially enabling the Justice Department to seize informational websites and intercept shipments. However, legal experts characterize this strategy as unnecessarily complex and impractical, suggesting it reflects the anti-abortion movement's frustration with President Trump's reluctance to pursue more direct enforcement methods, such as invoking the Comstock Act.

Who is affected

  • Individuals seeking medication abortions using mifepristone
  • Organizations providing information about ordering mifepristone from other countries (whose website domains could be seized)
  • Overseas pharmaceutical manufacturers, particularly those in India
  • Telehealth providers prescribing medication abortion
  • Anti-abortion organizations like the Charlotte Lozier Institute and SBA Pro-Life America
  • Attorney General Todd Blanche and the Department of Justice
  • President Donald Trump's administration

What action is being taken

  • The Charlotte Lozier Institute is preparing to unveil a forthcoming research paper detailing how the Justice Department could use Operation Pangea
  • Trump's FDA announced in June that it would conduct a six-month review of mifepristone's safety
  • Legal challenges filed by anti-abortion states related to mifepristone's FDA approval and Biden-era telemedicine changes are proceeding through the courts

Why it matters

  • This matters because medication abortion now represents 63 percent of all U.S. abortions, with roughly 28 percent conducted via telehealth, making mifepristone restriction a top priority for the anti-abortion movement since Roe v. Wade was overturned in 2022. The proposed strategy represents a new frontier in abortion regulation that could significantly impact access to medication abortion nationwide, even as overall abortion numbers have increased despite state-level bans. The convoluted approach reflects growing tension between anti-abortion advocates and the Trump administration, which has thus far declined to prioritize aggressive enforcement actions like invoking the Comstock Act, despite Trump's previous promises to be the "most pro-life president in history." The effort's success or failure could determine whether abortion opponents can curtail the widespread availability of medication abortion that has helped maintain abortion access despite state restrictions.

What's next

  • Mary Harned will release a research paper detailing how Operation Pangea could be used against mifepristone distribution
  • The FDA's six-month review of mifepristone's safety is ongoing
  • Legal challenges related to mifepristone's FDA approval and Biden-era regulatory changes will continue to proceed through the courts
  • Sen. Josh Hawley's legislation to undo FDA's mifepristone approval remains pending (though has not advanced since March introduction)

Read full article from source: The 19th